Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact

Publisher： Karger

E-ISSN： 1423-0232|84|3|150-157

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.3, 2012-12, pp. : 150-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 844-853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration

By  

CYTOPATHOLOGY, Vol. 29, Iss. 1, 2018-02 ,pp. : 35-40

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 111-116

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of the Epidermal Growth Factor Receptor in Breast Cancer

By Chan Samuel   Hill Mark   Gullick William  

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 3-11

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite